大麻二酚治疗Dravet综合征的随机剂量探索安全性试验
这项随机双盲试验将4-10岁Dravet综合征患儿按4:1随机分配至大麻二酚(CBD)5、10或20 mg/kg/d组或安慰剂组,评估安全性和初步药代动力学。结果显示CBD暴露随剂量成比例增加,与N-CLB存在相互作用,CBD组不良事件多于安慰剂但总体耐受良好,提供I级证据。
要点
- CBD暴露及其代谢物随剂量成比例增加(AUC0-t)。
- CBD与N-CLB存在相互作用,可能与抑制CYP2C19有关。
- CBD组不良事件多于安慰剂,但总体耐受良好(I级证据)。
核心结论
- CBD及其代谢物暴露随剂量成比例增加,与N-CLB存在相互作用,可能源于CBD抑制细胞色素P450 2C19亚型。
- CBD所致不良事件多于安慰剂,但总体耐受良好;该研究为Dravet综合征患儿提供I级证据。
研究设计与样本
- 随机、双盲、剂量探索试验,4-10岁Dravet综合征患者按4:1随机分配至CBD 5、10或20 mg/kg/d组或安慰剂组,每日两次给药。
- 试验包括4周基线期、3周治疗期(含滴定)、10天逐渐减量期和4周随访期;完成者可继续进入开放标签扩展期。
- 共34例患者随机(5、10、20 mg/kg/d CBD组分别10、8、9例,安慰剂组7例),32例(94%)完成治疗。
主要发现
- CBD及其代谢物6-OH-CBD、7-OH-CBD、7-COOH-CBD的暴露随剂量成比例增加(AUC0-t)。
- CBD不影响合并抗癫痫药物水平,但N-CLB升高(服用司替戊醇的患者除外)。
- CBD组最常见不良事件为发热、嗜睡、食欲下降、镇静、呕吐、共济失调和异常行为。
- 6例同时服用CBD和丙戊酸的患者出现转氨酶升高,均未达到药物性肝损伤标准并全部恢复;未观察到其他有临床意义的安全性信号。
关键数值与推荐
- CBD暴露及其代谢物随剂量成比例增加(AUC0-t)。
- CBD与N-CLB存在相互作用,可能与抑制细胞色素P450 2C19亚型有关。
- CBD组不良事件多于安慰剂组,但总体耐受良好(I级证据)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS: Patients aged 4-10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers could continue in an open-label extension. Multiple pharmacokinetic blood samples were taken on the first day of dosing and at end of treatment for measurement of CBD, its metabolites 6-OH-CBD, 7-OH-CBD, and 7-COOH-CBD, and antiepileptic drugs (AEDs; clobazam and metabolite N-desmethylclobazam [N-CLB], valproate, levetiracetam, topiramate, and stiripentol). Safety assessments were clinical laboratory tests, physical examinations, vital signs, ECGs, adverse events (AEs), seizure frequency, and suicidality. RESULTS: Thirty-four patients were randomized (10, 8, and 9 to the 5, 10, and 20 mg/kg/d CBD groups, and 7 to placebo); 32 (94%) completed treatment. Exposure to CBD and its metabolites was dose-proportional (AUC0-t). CBD did not affect concomitant AED levels, apart from an increase in N-CLB (except in patients taking stiripentol). The most common AEs on CBD were pyrexia, somnolence, decreased appetite, sedation, vomiting, ataxia, and abnormal behavior. Six patients taking CBD and valproate developed elevated transaminases; none met criteria for drug-induced liver injury and all recovered. No other clinically relevant safety signals were observed. CONCLUSIONS: Exposure to CBD and its metabolites increased proportionally with dose. An interaction with N-CLB was observed, likely related to CBD inhibition of cytochrome P450 subtype 2C19. CBD resulted in more AEs than placebo but was generally well-tolerated. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.
引用
- Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018. PMID: 29540584. doi:10.1212/WNL.0000000000005254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。